MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Kodu・Aktsiate loetelu・Krystal Biotech Inc

Krystal Biotech Inc

Suletud

SektorTervishoid

181.65 1.53

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

177.07

Max

181.65

Põhinäitajad
By Trading Economics
Sissetulek	2.6M 38M
Müük	7.9M 96M
P/E Sektori keskmine	34.122 35.739
Kasumimarginaal	39.914
Töötajad	275
EBITDA	1.5M 39M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+12.4% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. nov 2025

Turustatistika
By TradingEconomics
Turukapital	1.2B 5.1B
Eelmine avamishind	180.12
Eelmine sulgemishind	181.65

Uudiste sentiment

By Acuity

50%

149 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

133.221 / 169.73 Toetus ja vastupanu

Krystal Biotech Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. okt 2025, 23:30 UTC

Kuumad aktsiad

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. okt 2025, 21:21 UTC

Tulu

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. okt 2025, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. okt 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. okt 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. okt 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Scales's JV Buyout Lauded by Bull -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Forex and Fixed Income Roundup: Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. okt 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. okt 2025, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

2. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. okt 2025, 20:49 UTC

Omandamised, ülevõtmised, äriostud

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. okt 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. okt 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. okt 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. okt 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. okt 2025, 18:43 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Võrdlus sarnastega

Hinnamuutus

Krystal Biotech Inc Prognoos

Hinnasiht

By TipRanks

12.4% tõus

12 kuu keskmine prognoos

Keskmine 201.88 USD 12.4%

Kõrge 240 USD

Madal 166 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Krystal Biotech Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Krystal Biotech Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

133.221 / 169.73Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

149 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.